These findings strongly suggest that in preclinical studies, DNA vaccination with ITI-3000, using the UNITETM platform, enhances CD4 T cell responses to MCPyV-LT that result in significant anti-tumor immune responses. This evidence concerns the gene CD4 and neoplasm.